Paul Moser

Paul Moser has extensive experience in the field of psychopharmacology and neuroscience drug development, having held key positions in various companies since the late 1970s. Moser began as a Research Pharmacologist at Wyeth, later progressing through roles including Research Scientist at Merrell Dow and Group Leader of Psychopharmacology at Sanofi-Synthélabo Research. Moser has served as Director of Neuropsychopharmacology at Pierre Fabre and Director of Pharmacology at BIAL. Currently, Moser is an Associate Editor in Psychopharmacology for Frontiers, and President of Cerbascience SAS, a consulting firm focused on CNS drug development. Moser has also acted as a Member of the Scientific Advisory Board for Theranexus and holds a PhD in Chronopharmacology from the University of Bath and a BSc in Pharmacology from the University of Bristol.